Study of relationship between levels of hepcidine hormone and GDF15 for patients with prostatic cancer and their clinical importance

Prostate cancer (PCa) is a considered of malignancy worldwide, particularly among the elderly. In Europe, about 417.000 men were diagnosed with PCa for the first time in 2012. Since PCa is so diverse, there is a growing The development of novel biomarkers capable of predicting prognosis, cancer incidence, therapy effectiveness,& patient outcomes is critical. Additionally, biomarkers are required in advanced PCa that has progressed to CRPC following first therapy, it is possible to anticipate tumor growth and aggressiveness in connection to a range of potentially life-extending drugs. Hepcidin and Growth Differentiation Factor 15 have been shown to be present in significant concentrations in a variety of cancers (GDF-15). The levels of serum hepcidin and GDF-15 have been proven to be prognostic markers in cancer patients in the past. To determine the significance of hepcidin, Growth Differentiation Factor 15, Prostate Specific Antigen,& several other associated Harmons in the prediction or early detection of prostate cancer, the investigators conducted a research. As a result, this research will be regarded as significant in the area of Iraqi patients.. There were substantial disparities in our research. (P ≤ 0.05) with Hepcidin Hormone (H. H.), C Reactive Protein (C-RP), Growth Differentiation Factor 15 (Gdf15),& Follicle Stimulating Hormone (FSH), Because of the high importance (correlation) shown by our study (H.H, C-RP, GDF15,& PSA) between the Patient Group and Control Group, it can be used these variables to precise prediction of prostate diseases. There are relationships of strength between Hepcidin Hormone variables and some biochemical variables such as Age, C - Reactive Protein (C-RP), Prostate-Specific Antigen (PSA),& Growth Differentiation Factor 15 (Gdf15). KEY WORD: Prostate Cancer, Hepcidine, GDF15 and PSA